Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 855

1.

Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery.

Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, Schrör K, Hohlfeld T.

Circulation. 2003 Aug 5;108(5):542-7. Epub 2003 Jul 21.

2.

Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting?

Zimmermann N, Kurt M, Wenk A, Winter J, Gams E, Hohlfeld T.

Eur J Cardiothorac Surg. 2005 Apr;27(4):606-10. Epub 2005 Jan 19.

PMID:
15784358
3.

Aspirin-induced platelet inhibition in patients undergoing cardiac surgery.

Zimmermann N, Kurt M, Winter J, Gams E, Wenzel F, Weber AA, Hohlfeld T.

Platelets. 2007 Nov;18(7):528-34.

PMID:
17957569
4.

COX-2 is not involved in thromboxane biosynthesis by activated human platelets.

Patrignani P, Sciulli MG, Manarini S, Santini G, Cerletti C, Evangelista V.

J Physiol Pharmacol. 1999 Dec;50(4):661-7.

PMID:
10639016
5.

Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting.

Mattiello T, Guerriero R, Lotti LV, Trifirò E, Felli MP, Barbarulo A, Pucci B, Gazzaniga P, Gaudio C, Frati L, Pulcinelli FM.

J Am Coll Cardiol. 2011 Aug 9;58(7):752-61. doi: 10.1016/j.jacc.2011.03.049. Erratum in: J Am Coll Cardiol. 2011 Oct 18;58(17):1832.

6.
7.

Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries.

Hennan JK, Huang J, Barrett TD, Driscoll EM, Willens DE, Park AM, Crofford LJ, Lucchesi BR.

Circulation. 2001 Aug 14;104(7):820-5.

8.

Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.

Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US.

Circulation. 2007 Jun 26;115(25):3156-64. Epub 2007 Jun 11.

9.

Selective and nonselective inhibition of thromboxane formation.

FitzGerald GA, Oates JA.

Clin Pharmacol Ther. 1984 May;35(5):633-40.

PMID:
6370554
10.

Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.

Rotondo S, Krauze-Brzósko K, Manarini S, Evangelista V, Cerletti C.

Eur J Pharmacol. 2004 Mar 19;488(1-3):79-83.

PMID:
15044038
11.

Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors.

Kobzar G, Mardla V, Samel N.

Platelets. 2011;22(5):338-44. doi: 10.3109/09537104.2010.535931. Epub 2011 May 11.

PMID:
21557683
12.

A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.

Greenberg HE, Gottesdiener K, Huntington M, Wong P, Larson P, Wildonger L, Gillen L, Dorval E, Waldman SA.

J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1509-15.

PMID:
11185674
13.

Aspirin is insufficient in inhibition of platelet aggregation and thromboxane formation early after coronary artery bypass surgery.

Bednar F, Osmancik P, Hlavicka J, Jedlickova V, Paluch Z, Vanek T.

J Thromb Thrombolysis. 2009 May;27(4):394-9. doi: 10.1007/s11239-008-0225-y. Epub 2008 May 1.

PMID:
18449473
14.
15.

Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.

Frelinger AL 3rd, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD.

Circulation. 2009 Dec 22;120(25):2586-96. doi: 10.1161/CIRCULATIONAHA.109.900589. Epub 2009 Dec 7.

17.

Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.

Guthikonda S, Mangalpally K, Vaduganathan M, Patel R, Delao T, Bergeron AL, Dong JF, Lev EI, Kleiman NS.

Thromb Haemost. 2008 Jul;100(1):83-9. doi: 10.1160/TH07-10-0590.

PMID:
18612542
18.

Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.

McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Lawrie AS, Purdy G, Machin SJ, Brown MM.

Platelets. 2005 Aug;16(5):269-80.

PMID:
16011977
19.

Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers.

Wilner KD, Rushing M, Walden C, Adler R, Eskra J, Noveck R, Vargas R.

J Clin Pharmacol. 2002 Sep;42(9):1027-30.

PMID:
12211219
20.

Alternative splicing of platelet cyclooxygenase-2 mRNA in patients after coronary artery bypass grafting.

Censarek P, Steger G, Paolini C, Hohlfeld T, Grosser T, Zimmermann N, Fleckenstein D, Schrör K, Weber AA.

Thromb Haemost. 2007 Dec;98(6):1309-15.

PMID:
18064329
Items per page

Supplemental Content

Write to the Help Desk